Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 1, 2013, Pages

  Gatto, Federico ^a   Feelders, Richard A ^a   Van Der Pas, Rob ^a   Kros, Johan M ^a   Waaijers, Marlijn ^a   Sprij Mooij, Diana ^a   Neggers, Sebastian J C M M ^a   Van Der Lelij, Aart Jan ^a   Minuto, Francesco ^b   Lamberts, Steven W J ^a   De Herder, Wouter W ^a   Ferone, Diego ^b   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; MONOCLONAL ANTIBODY; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 2A ANTIBODY; UNCLASSIFIED DRUG;

ACROMEGALY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOREACTIVITY SCORE; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE;

ACROMEGALY; ADENOMA; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, PHARMACOLOGICAL; CHEMOTHERAPY, ADJUVANT; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OCTREOTIDE; PROGNOSIS; RABBITS; RECEPTORS, SOMATOSTATIN; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SOMATOSTATIN; YOUNG ADULT;

ORYCTOLAGUS CUNICULUS;

EID: 84872070630     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2609     Document Type: Article

References (20)

1. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts SW 2004 The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89:1577-1585
2. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P 2001 Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 86:140-145
3. Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR 2008 Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 158:295-303
4. Wildemberg LE, Vieira Neto L, Costa DF, Nasciuti LE, Takiya CM, Alves LM, Rebora A, Minuto F, Ferone D, Gadelha MR 26 March 2012 Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2, expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest 10.3275/8305
5. Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW, Hofland LJ 2008 Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 93:1412-1417
6. Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J, Bollerslev J 2008 The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf) 68:458-465
7. Körner M, Waser B, Schonbrunn A, Perren A, Reubi JC 2012 Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol 36:242-252
8. Plöckinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S, Schulz S 2008 Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab 93:1203-1210
9. Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, Schulz S 2008 Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab 93:4519-4524
10. de Herder WW, Taal HR, Uitterlinden P, Feelders RA, Janssen JA, van der Lely AJ 2005 Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with sandostatin LAR in acromegaly. Eur J Endocrinol 153:67-71
11. Remmele W, Stegner HE 1987 [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8:138-140
12. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A 2009 Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517
13. Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A, Jaquet P 1998 Pronostic and therapeutic consequences of Gs α mutations in somatotroph adenomas. J Clin Endocrinol Metab 83:1604-1610
14. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola B, Salvatore M, Lombardi G 1996 Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81:2356-2362
15. Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA 2005 The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol (Oxf) 62:282-288
16. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D 2005 Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465-4473
17. Correa LL, Taboada GF, Van Haute FR, Casini AF, Balarini GA, Vieira Neto L, Machado Ede O, Fontes R, Andrade CC, Schrank Y, Gadelha MR 2008 [Evaluation of glucose metabolism in acromegalic patients before and after treatment with octreotide LAR]. Arq Bras Endocrinol Metabol 52:55-64
18. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH 2000 Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 85:781-792
19. Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L, Schindler M, Cole SL, Bussolati G 2002 Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440:461-475
20. Colao A, Auriemma RS, Lombardi G, Pivonello R 2011 Resistance to somatostatin analogs in acromegaly. Endocr Rev 32:247-271